Changes of intestinal microflora of breast cancer in premenopausal women

He, Chuan; Liu, Yue; Ye, Shandong; Yin, Shiwu; Gu, Junfei

doi:10.1007/s10096-020-04036-x

Cited by 42 publications

(35 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 Preclinical studies in a mouse model showed that infection with Citrobacter increased epithelial cell proliferation and promoted growth of chemically-induced colon tumors. 46 In contrast to previous studies, 18 , 47 , 48 Clostridium richness was found in patients with benign breast tumor than in those with malignant tumor. Diversity in the gut microbiota composition of patients with breast carcinoma suggests that microbial metabolism or dysbiosis may play an important role in breast cancer development.…”

Section: Discussioncontrasting

confidence: 86%

Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study

Yang

Wang

Peng

et al. 2021

Evol Bioinform Online

View full text Add to dashboard Cite

The microbiome plays diverse roles in many diseases and can potentially contribute to cancer development. Breast cancer is the most commonly diagnosed cancer in women worldwide. Thus, we investigated whether the gut microbiota differs between patients with breast carcinoma and those with benign tumors. The DNA of the fecal microbiota community was detected by Illumina sequencing and the taxonomy of 16S rRNA genes. The α-diversity and β-diversity analyses were used to determine richness and evenness of the gut microbiota. Gene function prediction of the microbiota in patients with benign and malignant carcinoma was performed using PICRUSt. There was no significant difference in the α-diversity between patients with benign and malignant tumors ( P = 3.15e−1 for the Chao index and P = 3.1e−1 for the ACE index). The microbiota composition was different between the 2 groups, although no statistical difference was observed in β-diversity. Of the 31 different genera compared between the 2 groups, level of only Citrobacter was significantly higher in the malignant tumor group than that in benign tumor group. The metabolic pathways of the gut microbiome in the malignant tumor group were significantly different from those in benign tumor group. Furthermore, the study establishes the distinct richness of the gut microbiome in patients with breast cancer with different clinicopathological factors, including ER, PR, Ki-67 level, Her2 status, and tumor grade. These findings suggest that the gut microbiome may be useful for the diagnosis and treatment of malignant breast carcinoma.

show abstract

Section: Discussioncontrasting

confidence: 86%

Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study

Yang

Wang

Peng

et al. 2021

Evol Bioinform Online

View full text Add to dashboard Cite

show abstract

“…Additionally, a study of the gut microbiota composition of premenopausal patients with BrCa identified a reduction in the abundance of SCFA producing Pediococcus species compared to normal premenopausal women. The same study demonstrated the anti-cancer effects of butyrate and propionate on human BrCa cells in vitro ( He et al., 2021 ). Contrastingly, inoculation of mice harboring subcutaneous melanomas with Bifidobacterium , a known beneficial “probiotic” genus, has been shown to amplify the anti-tumor effect of an anti-PD-L1 immunotherapy through the priming of CD8 + T lymphocytes ( Sivan et al., 2015 ).…”

Section: Introductionmentioning

confidence: 82%

Section: Introductionmentioning

confidence: 84%

Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth

McKee¹,

Kirkup²,

Madgwick³

et al. 2021

iScience

View full text Add to dashboard Cite

show abstract

“…Interestingly, studies have demonstrated key microbial changes in premenopausal patients at time of breast cancer diagnosis, suggesting that specifically SCFA-producing microbes are significantly lower in abundance in premenopausal breast cancer patients [112]. Furthermore, the SCFAs propionate and butyrate have been shown to inhibit breast cancer cell growth in vitro [112]. Valproic acid, a histone deacetylase inhibitor, has recently been demonstrated to inhibit growth of glioma cells in models of high-grade gliomas [113].…”

Section: Scfa From Microbial Metabolismmentioning

confidence: 99%

“…Pasteurellales [118] Alcohol consumption and high temperature beverages [119] Fruit and vegetable [120] Polyphenols [76,100] Breast Bacteroides plebeius [54,55] Acid-producing diets [121,122] B-glucuronidase [63] Valproic acid [123,124] Seaweed [54,55] Sodium propionate [45] Sodium butyrate [102][103][104][105][106] Mediterranean diet [112,123,124] Sorbate [47] Benzoate [47] Ovarian Clostridia [125] Valproic acid [90] Vitamin D [35] Prostate Possibly Enterobacteriaceae and Proteobacteria [73] High-fat (keto) diet [72] SCFA [72,126] Sodium phenylbutyrate [107,108,110] Sodium butyrate [102][103][104][105][106]…”

Section: Cancer Type Possible Microbes Involved Dietary Risk Factors mentioning

confidence: 99%

The Multifaceted Roles of Diet, Microbes, and Metabolites in Cancer

Armstrong

Bording-Jorgensen

Wine

2021

Cancers

View full text Add to dashboard Cite

Many studies performed to date have implicated select microbes and dietary factors in a variety of cancers, yet the complexity of both these diseases and the relationship between these factors has limited the ability to translate findings into therapies and preventative guidelines. Here we begin by discussing recently published studies relating to dietary factors, such as vitamins and chemical compounds used as ingredients, and their contribution to cancer development. We further review recent studies, which display evidence of the microbial-diet interaction in the context of cancer. The field continues to advance our understanding of the development of select cancers and how dietary factors are related to the development, prevention, and treatment of these cancers. Finally, we highlight the science available in the discussion of common misconceptions with regards to cancer and diet. We conclude this review with thoughts on where we believe future research should focus in order to provide the greatest impact towards human health and preventative medicine.

show abstract

Changes of intestinal microflora of breast cancer in premenopausal women

Cited by 42 publications

References 39 publications

Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study

Comparison of the Gut Microbiota in Patients with Benign and Malignant Breast Tumors: A Pilot Study

Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth

The Multifaceted Roles of Diet, Microbes, and Metabolites in Cancer

Contact Info

Product

Resources

About